LUND, Sweden, Nov. 28, 2018 /PRNewswire/ -- Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company's lead products Buvidal® Weekly and Buvidal® ...
LUND, Sweden, April 9, 2019 /PRNewswire/ -- Camurus' (NASDAQ STO: CAMX) US partner, Braeburn Inc., today announced that the company today will file an action in federal district court for the District ...
Camurus, a Swedish research-based pharmaceutical company, announced that the European Commission (EC) has approved weekly and monthly Buvidal (prolonged release buprenorphine) for the treatment of ...
LUND, Sweden, Nov. 26, 2019 /PRNewswire/ -- Camurus announced today topline results from the 24-week, randomized, controlled, open-label, DEBUT study of weekly and monthly Buvidal® (prolonged-release ...
LUND, Sweden, Sept. 21, 2018 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use, CHMP, has adopted a ...
LUND, Sweden, Dec. 18, 2020 /PRNewswire/ -- Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ® ...
The full CMI on the next page has more details. If you are worried about being given this medicine, speak to your doctor, nurse practitioner or pharmacist. Buvidal contains the active ingredient ...
- Buvidal(R) is the first long-acting medicine approved in the EU for the treatment of opioid dependence in adults and adolescents Camurus announced today that the European Commission has granted ...
LUND, Sweden, Nov. 28, 2018 /PRNewswire/ -- Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company's lead products Buvidal Weekly and Buvidal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results